Fig 2: Combined application of CXCR2 inhibitor SB225002 and anti-PD-L1 dramatically blocks HOXC10-mediated CRC metastasis. (A-E). One week after injection of MC38-HOXC10 cells, mice in four groups were treated with vehicle, PD-L1 antibody or/and SB225002 (n=10 mice/group) until treatment endpoint. In vivo assays showed that combined treatment of PD-L1 antibody and CXCR2 inhibitors SB225002 can almost inhibit CRC metastasis. (A). Representative bioluminescent images and bioluminescent signals in indicated group. (B). Overall survival in indicated group. (C). The number of lung and liver nodules in indicated group. (D). The incidence of lung and liver nodules in indicated group. (E). Representative HE staining of lung and liver tissues. (F). IHC staining detected the infiltration of MDSCs or CD8+ cells in indicated group. All the data are shown as the mean±s.d. * P<0.05.

Fig 3: LNC00887 promotes ccRCC progression through CD8+ T cell-mediated immune response. (a) Effects of knocking down LNC00887 on ccRCC cells and PD-L1 were revealed by western blot assay. (b) The cytokilling ability of CD8+ T cells was evaluated by LDH assay. (c) Apoptosis of CD8+ T cells was detected by flow cytometry. (d) The chemotactic ability of CD8+ T cells was evaluated by chemotactic assay. (e) Expression of CXCL9, CXCL10, and CXCR3 in CD8+ T cells was evaluated by RT-qPCR, ∗P < 0.05.

Fig 4: Bioinformatics prediction of correlation between LINC00887 expression and CD8+ T cell immune infiltration. (a) KEGG enrichment analysis of DEGs between LINC00887 high- and low-expression groups. (b) GO enrichment analysis of DEGs between LINC00887 high- and low-expression groups. (c) Relative infiltration abundance of 21 kinds of immune cells in ccRCC samples. (d) Differences in immune cell infiltration between LINC00887 high- and low-expression groups. (e) Correlation analysis between LINC00887 expression and immune cell infiltration abundance, ∗P < 0.05.

Fig 5: Immunohistochemistry (IHC) of CD3, CD8, and FoxP3 T lymphocytes in CRC. Representative IHC showing low and high CD3+, CD8+, and FoxP3+ T lymphocytes densities. Magnification: 200×.